MedTrace Logo

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

NCT05704621 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2025-03-06

No results posted yet for this study

Summary

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

Conditions

Interventions

PROCEDURE

secondary cytoreductive surgery

Maximum effort cytoreductive surgery

DRUG

chemotherapy

six cycles of platinum-based chemotherapy +/- bevacizumab

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Chong Kun Dang Pharmaceutical Corp.

    collaborator INDUSTRY

  • Yonsei University

    collaborator OTHER

  • KGOG: Korean Gynaelogical Onology Group, Korea

    collaborator UNKNOWN

  • Japanese Gynecologic Oncology Group

    collaborator OTHER

  • Asia-Pacific Gynecologic Oncology Trials Group (APGOT)

    collaborator UNKNOWN

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Hyun-Woong Cho, MD. PhD. · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2026-12-28
Completion
2028-12-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05704621 on ClinicalTrials.gov